4/10
08:00 am
atos
Atossa Genetics (ATOS) had its price target lowered by Ascendiant Capital Markets from $120.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Atossa Genetics (ATOS) had its price target lowered by Ascendiant Capital Markets from $120.00 to $24.00. They now have a "buy" rating on the stock.
3/26
08:19 am
atos
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
3/26
12:54 am
atos
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
High
Report
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
3/25
06:10 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/25
05:30 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
3/19
08:00 am
atos
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Low
Report
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
3/12
08:21 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/12
08:00 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Low
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2/11
08:30 am
atos
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
High
Report
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
2/5
08:30 am
atos
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Medium
Report
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program